巨人症治療市場－全球產業規模、佔有率、趨勢、機會及預測（按藥物、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年）

全球肢端肥大症治療市場預計將從 2025 年的 17.2 億美元成長到 2031 年的 25.7 億美元，複合年成長率為 6.92%。

該市場涵蓋藥物、放射學和外科手術干預（特別是生長抑制素類似物和生長激素受體拮抗劑），旨在調節腦下垂體腺瘤引起的荷爾蒙過度分泌。成長的主要驅動力是先進治療方案的推出，這些方案提高了患者的依從性，並且由於篩檢技術的改進，診斷率也隨之提高。根據2025年內分泌學會的數據，肢端肥大症患者罹患白血病或淋巴瘤的風險比一般人高3.3倍，顯示有效的疾病管理對於預防嚴重併發症至關重要。

然而，終身藥物治療的高昂費用仍然是市場擴張的主要障礙，限制了醫療資源匱乏地區病患的就醫途徑。這些必不可少的長期治療所帶來的經濟負擔，使得許多患者難以獲得持續的治療。因此，這些經濟限制限制了全球市場的潛在收益，尤其是在發展中地區，因為這些地區的資金籌措框架無法支持如此昂貴的長期治療方案。

市場促進因素

新型口服和長效療法的商業化正在重塑全球肢端肥大症治療市場，解決了長期注射治療的難題。製藥公司正優先開發非胜肽口服製劑和緩釋注射劑，以提高患者的生活品質和依從性，並有效減輕終身治療的後勤負擔。這種以患者為中心的創新趨勢得到了臨床試驗高保留率的支持。例如，在2025年7月舉行的ENDO 2025會議上，Crinetics Pharmaceuticals公司報告稱，PATHFNDR-2試驗中97.2%的受試者選擇繼續服用口服藥物帕妥昔汀，這表明患者對非侵入性治療方法的需求十分強勁。

同時，先進生物標記和診斷成像技術的廣泛應用使得早期檢測和適當干預成為可能，從而推動了市場成長。專科內分泌中心強化篩檢通訊協定，識別出更多先前未確診的患者，並促使標靶治療處方量增加。這一趨勢也反映在主要企業的財務表現中。 Recodati在2025年2月發布的「2024會計年度初步表現」中預測，其內分泌部門的營收將成長32.8%，達到3.217億歐元。此外，該公司報告稱，其罕見疾病部門在2025會計年度上半年的營收年增29.2%，顯示該領域持續保持成長動能。

市場挑戰

終身藥物治療的高昂費用是全球肢端肥大症治療市場成長的主要障礙。生長抑制素類似物和生長激素受體拮抗劑是疾病控制的關鍵藥物，但其高昂的價格造成了嚴重的用藥障礙。這些治療方法屬於維持治療而非根治性治療，需要長期用藥，由此產生的累積經濟負擔對許多醫療預算而言難以承受。高昂的費用直接限制了發展中地區的市場滲透率，因為這些地區的健保體係不足以涵蓋昂貴且長期的治療費用。

此外，即使在有完善保險體系的市場中，經濟負擔也往往轉嫁到病人身上，導致用藥依從性差，甚至中斷治療。 2025年，HealthWell基金會報告稱，肢端肥大症患者平均每年需要使用2,200美元的津貼來彌補自付費用的差額。這些數據凸顯了患者面臨的巨大經濟負擔，這直接阻礙了他們堅持用藥。因此，經濟拮据使得許多確診患者無法獲得或繼續接受必要的治療，也阻​​礙了市場充分發揮其獲利潛力。

市場趨勢

學名藥進入肢端肥大症治療領域，從根本上改變了競爭格局，打破了品牌生長抑制素類似物長期以來的價格障礙。隨著關鍵生物製劑專利的到期，製造商正在推出複雜、低成本且生物等效的非專利藥製劑，擴大了先前受報銷限制的患者獲得治療的機會。這些具成本效益替代藥物的湧入正在迅速蠶食品牌藥的市場佔有率。根據梯瓦製藥公司預測，截至2025年1月，其美國學名藥業務預計將在2024年成長15%，這主要得益於首個SandostatinLAR緩釋學名藥的上市。

同時，以患者為中心的自我給藥裝置的整合正在革新疾病管理，將治療從醫療機構轉移到患者家中。研發人員將緩釋製劑與先進的給藥技術（例如預填充自動注射器）結合，以避免醫護人員進行侵入性注射。這一趨勢減輕了患者頻繁就診和相關疼痛的負擔，同時提高了用藥依從性和患者的自主性。作為這項進展的象徵，Camulus公司在2026年1月的新聞稿中宣布，其每月一次的皮下注射Octreotide製劑Ocryse（用於自我給藥）已於2025年在歐盟和英國獲得上市核准。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球巨人症治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物治療（生長抑制素類似物、生長激素受體拮抗劑、多巴胺促效劑、聯合治療）
  • 給藥途徑（口服、皮下注射、其他）
  • 按分銷管道（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美巨人症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲巨人症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區巨人症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲巨人症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲巨人症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球巨人症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Recordati SpA
• Pfizer Inc.
• Validus Pharmaceuticals LLC
• Ipsen SA
• Crinetics Pharmaceuticals, Inc.
• Amryt Pharma plc
• Debiopharm International SA
• ADVANZ PHARMA CORP.
• Novartis Pharmaceuticals Corporation
• Amolyt Pharma SAS

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Acromegaly Treatment Market is projected to expand from USD 1.72 Billion in 2025 to USD 2.57 Billion by 2031, registering a CAGR of 6.92%. This market includes pharmacological, radiological, and surgical interventions-specifically somatostatin analogs and growth hormone receptor antagonists-aimed at regulating hormonal hypersecretion typically caused by pituitary adenomas. Growth is primarily fueled by the introduction of advanced therapeutic formulations that improve patient compliance, as well as increased diagnosis rates due to better screening technologies. Data from the Endocrine Society in 2025 indicated that acromegaly patients face a 3.3 times higher risk of leukemia or lymphoma compared to the general population, highlighting the critical need for effective disease management to prevent severe comorbidities.

However, market expansion is significantly hindered by the prohibitive costs of lifelong pharmacological therapy, which limits patient access in regions with inadequate healthcare reimbursement systems. The financial burden of these essential, indefinite treatments restricts the ability of many patients to receive consistent care. Consequently, these economic constraints impede the broader reach and potential revenue realization of the global market, particularly in developing areas where funding frameworks cannot support such expensive, long-term regimens.

Market Driver

The commercialization of novel oral and long-acting therapeutics is reshaping the Global Acromegaly Treatment Market by addressing the challenges of chronic injectable regimens. Pharmaceutical developers are prioritizing non-peptide oral formulations and extended-release injectables to enhance patient quality of life and compliance, effectively reducing the logistical burdens of lifelong therapy. This shift toward patient-centered innovation is supported by strong clinical trial retention; for instance, Crinetics Pharmaceuticals reported at 'ENDO 2025' in July 2025 that 97.2% of eligible participants in the PATHFNDR-2 study chose to continue with the oral drug paltusotine, signaling a robust demand for non-invasive options.

Simultaneously, the widespread adoption of advanced biomarkers and diagnostic imaging is driving market growth by facilitating earlier detection and timely intervention. Enhanced screening protocols in specialized endocrinology centers are identifying previously undiagnosed patients, leading to increased prescription volumes for targeted therapies. This trend is reflected in the financial performance of key players; Recordati's 'Preliminary Results for Full Year 2024' in February 2025 showed a 32.8% revenue increase in their Endocrinology franchise, reaching €321.7 million. Furthermore, Recordati reported that revenue for its Rare Diseases unit grew by 29.2% in the first half of 2025 compared to the prior period, illustrating the sector's sustained momentum.

Market Challenge

The prohibitive cost of lifelong pharmacological therapy represents a major obstacle to the growth of the Global Acromegaly Treatment Market. While somatostatin analogs and growth hormone receptor antagonists are vital for managing the disease, their high pricing creates significant accessibility barriers. Since these interventions are maintenance therapies rather than cures, they require indefinite administration, resulting in a cumulative financial burden that many healthcare budgets cannot sustain. This high cost directly limits market penetration in developing regions where reimbursement frameworks are insufficient to cover such expensive, long-term regimens.

Moreover, even in markets with established insurance systems, the economic strain is frequently shifted to patients, leading to reduced adherence and treatment discontinuation. In 2025, the HealthWell Foundation reported that patients diagnosed with acromegaly utilized an average of $2,200 in annual grant funding specifically to bridge the gap for out-of-pocket expenses. This data underscores the financial toxicity facing patients, which directly hampers the consistent consumption of therapeutics. Consequently, the market struggles to realize its full revenue potential as economic constraints prevent a large portion of the diagnosed population from accessing or maintaining necessary care.

Market Trends

The entry of generic acromegaly therapeutics is fundamentally altering the competitive landscape by dismantling the long-standing price barriers associated with branded somatostatin analogs. As patents for major biologics expire, manufacturers are introducing complex generic formulations that offer bioequivalent efficacy at reduced costs, thereby expanding treatment access for patient populations previously restricted by reimbursement limitations. This influx of cost-effective alternatives is rapidly capturing market share from originator products; according to Teva Pharmaceuticals in January 2025, their U.S. Generics business grew by 15% in 2024, a performance significantly bolstered by the launch of the first generic version of Sandostatin LAR Depot.

Concurrently, the integration of patient-centric self-administration devices is revolutionizing disease management by shifting care from clinical settings to the patient's home. Developers are coupling prolonged-release formulations with advanced delivery technologies, such as pre-filled autoinjectors, to eliminate the need for invasive injections administered by healthcare professionals. This trend addresses the burden of frequent clinic visits and associated pain, enhancing adherence and patient autonomy. Highlighting this progress, Camurus confirmed in a January 2026 press release that its novel once-monthly subcutaneous octreotide depot, Oclaiz, designed for self-administration, received marketing authorization in the European Union and the United Kingdom in 2025.

Key Market Players

• Recordati S.p.A.
• Pfizer Inc.
• Validus Pharmaceuticals LLC
• Ipsen S.A.
• Crinetics Pharmaceuticals, Inc.
• Amryt Pharma plc
• Debiopharm International SA
• ADVANZ PHARMA CORP.
• Novartis Pharmaceuticals Corporation
• Amolyt Pharma SAS

Report Scope

In this report, the Global Acromegaly Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acromegaly Treatment Market, By Drugs

• Somatostatin Analogs
• Growth Hormone Receptor Antagonists
• Dopamine Agonists
• Combination Therapy

Acromegaly Treatment Market, By Route of administration

• Oral
• Subcutaneous
• Others

Acromegaly Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Acromegaly Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acromegaly Treatment Market.

Available Customizations:

Global Acromegaly Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acromegaly Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Somatostatin Analogs, Growth Hormone Receptor Antagonists, Dopamine Agonists, Combination Therapy)
  • 5.2.2. By Route of administration (Oral, Subcutaneous, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Acromegaly Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Route of administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acromegaly Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Route of administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Acromegaly Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Route of administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Acromegaly Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Route of administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Acromegaly Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Route of administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acromegaly Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Route of administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Acromegaly Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Route of administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Acromegaly Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Route of administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Acromegaly Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Route of administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Acromegaly Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Route of administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Acromegaly Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Route of administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acromegaly Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Route of administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Acromegaly Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Route of administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Acromegaly Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Route of administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Acromegaly Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By Route of administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Acromegaly Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By Route of administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Acromegaly Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Route of administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acromegaly Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Route of administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Acromegaly Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Route of administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Acromegaly Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Route of administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Acromegaly Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Route of administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acromegaly Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Route of administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Acromegaly Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Route of administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Acromegaly Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Route of administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acromegaly Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Recordati S.p.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Validus Pharmaceuticals LLC
• 15.4. Ipsen S.A.
• 15.5. Crinetics Pharmaceuticals, Inc.
• 15.6. Amryt Pharma plc
• 15.7. Debiopharm International SA
• 15.8. ADVANZ PHARMA CORP.
• 15.9. Novartis Pharmaceuticals Corporation
• 15.10. Amolyt Pharma SAS

16. Strategic Recommendations

17. About Us & Disclaimer